Furthermore, nano-bodies are less likely to cause cytotoxicity triggered by complement activation, as they lack the Fc-region.152The first anti-vWF-nano-body will likely be approved for the treatment of TTP, due to positive results of recent Phase II/III trials.46, 153. Here, VWF is linked to thrombotic thrombocytopenic purpura.